Surgery Partners, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting third-quarter revenue of $815.3 million and a net loss attributable to the company of $21.1 million.

Key Highlights

  • Revenue: Revenues for the three months ended September 30, 2026 were $815.3 million, compared with $821.5 million in the same period of 2025.
  • Net loss attributable to Surgery Partners: The company reported a net loss of $21.1 million for Q3 2026, versus a net loss of $22.7 million in Q3 2025.
  • Basic and diluted loss per share: $(0.16) for Q3 2026, compared with $(0.18) in Q3 2025.
  • Nine-month revenue: Revenues for the nine months ended September 30, 2026 totaled $2,475.1 million, up from $2,423.7 million in the prior-year period.
  • Total assets: Total assets stood at $7,049.8 million as of September 30, 2026, down from $8,119.7 million as of December 31, 2025.
  • Long-term debt: Long-term debt, less current maturities, was $2,998.7 million at September 30, 2026, compared with $3,602.9 million at December 31, 2025.
  • Shares outstanding: As of November 2, 2026, there were 130,881,223 shares of common stock outstanding.

Surgery Partners Q3 2026 Financial Results: Revenue, Costs, and Balance Sheet

According to the filing, Surgery Partners (NASDAQ:SGRY) reported revenues of $815.3 million for the three months ended September 30, 2026, a decrease from $821.5 million in the year-ago quarter. Cost of revenues for the same period was $630.3 million, up from $626.2 million in Q3 2025. General and administrative expenses rose to $40.6 million from $22.4 million in Q3 2025. The company also reported a loss on debt extinguishment of $3.7 million in Q3 2026, compared with $1.3 million in Q3 2025.

The filing disclosed that operating income for Q3 2026 was $85.6 million, down from $105.7 million in Q3 2025. Net interest expense was $67.9 million for the quarter, resulting in income before income taxes of $17.7 million. After accounting for income tax expense of $3.6 million and net income attributable to non-controlling interests of $35.2 million, the net loss attributable to Surgery Partners, Inc. was $21.1 million, or $(0.16) per basic and diluted share. The filing noted that the impact of potentially dilutive securities was not considered because the effect would be anti-dilutive.

On the balance sheet, the company reported cash and cash equivalents of $354.5 million as of September 30, 2026, up from $239.9 million at December 31, 2025. Goodwill and other intangible assets, net, decreased to $4,643.5 million from $5,235.6 million. The retained deficit widened to $887.3 million from $815.2 million at year-end 2025. Non-controlling interests classified as redeemable were $356.8 million, and total stockholders' equity was $2,899.9 million, compared with $3,131.3 million at December 31, 2025.

What Was Disclosed

Surgery Partners filed its quarterly report for the period ended September 30, 2026, disclosing Q3 revenues of $815.3 million, a net loss attributable to the company of $21.1 million, total assets of $7,049.8 million, and 130,881,223 shares of common stock outstanding as of November 2, 2026.